115 results
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond
424B5
ppyjoix50kk31cx8mcfg
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
8qb3rlvqdsnlmo3lm0d
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
7njc4wp
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
g75rhyq1
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
zfsk3bzgjbnrt4gih
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
bob37v w65r
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
r2zgooi
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
rcog59
12 Dec 23
Current report (foreign)
7:07am
6-K
EX-99
k5c6a7p1c
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
gyix6n7c6rz so
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
fv6rvr1
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
5hrj7e 610klrrx
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
nd6oxgzu
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
hx3gzqurd7eplr87r
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am